Real-life use of apremilast for the treatment of psoriasis in patients with oncological comorbidities: a retrospective descriptive multicentre study in France. - Université de Lille Accéder directement au contenu
Article Dans Une Revue European Journal of Dermatology Année : 2023

Real-life use of apremilast for the treatment of psoriasis in patients with oncological comorbidities: a retrospective descriptive multicentre study in France.

Résumé

Psoriasis is a common inflammatory dermatosis with a strong impact on quality of life and associated comorbidities [1–6]. Treatment must be adapted to the severity of the disease and the patients’ comorbidities. Local treatments are the first line, as well as phototherapy. Then, in case of failure or more severe forms, conventional systemic treatments and biological therapies can be proposed. Apremilast (APR) is an oral phosphodiesterase inhibitor 4 [7], indicated for the treatment of [...]
Fichier non déposé

Dates et versions

hal-04517442 , version 1 (22-03-2024)

Identifiants

Citer

Pauline Podevin, Anne-Caroline Cottencin, Coralie Becquart, Selma Azib, Adeline Duparc, et al.. Real-life use of apremilast for the treatment of psoriasis in patients with oncological comorbidities: a retrospective descriptive multicentre study in France.. European Journal of Dermatology, 2023, European Journal of Dermatology, 33, pp.34-40. ⟨10.1684/ejd.2023.4407⟩. ⟨hal-04517442⟩

Collections

RIIP UNIV-LILLE
0 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More